CorMedix Inc. (CRMD) Deep Dive Video

Summary

CorMedix has evolved into a profitable, undervalued institutional anti-infectives platform with DefenCath at its core and major upside tied to reimbursement, REZZAYO, and TPN expansion.

View CRMD stock page · Read the CRMD research report

Loading the video player…